Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
•
HER+
What is your treatment approach in a male with ER+ Her2+ metastatic breast cancer who received TCHP but developed irreversible cardiomyopathy?
Related Questions
Under what circumstances, if any, do you offer treatment holidays when treating patients with metastatic HER2+ breast cancer?
What is your approach to treatment in hormone receptor positive, HER2 negative (0 IHC) metastatic breast cancer with ERBB2 gene amplification after progression on AI and fulvestrant CDK4/6i with visceral crisis?
How reliable is the liquid biopsy on patients with progressing HER2 positive breast cancer with negative HER2 on liquid testing?
What factors do you use to decide between trastuzumab-deruxtecan and sacituzumab govitecan in HER2-low metastatic breast cancer?
Do you routinely check echocardiograms on all patients who are starting TDM1?
Do you switch therapy to sacituzumab in a patient with metastatic HR+ HER2- breast cancer who has stable systemic disease but new <1cm brain metastasis?
Do you recommend the use of elacestrant after prior fulvestrant in metastatic hormone positive breast cancer?
How long would you continue trastuzumab and pertuzumab in a patient with ER+ HER2+ breast cancer with initially osseous involvement treated with ACT-HP and is now in CR by PET for >2 years?
Are there scenarios where you would consider use of capivasertib for non-AKT pathway altered patients given the efficacy seen in the overall treatment population of the CAPItello-291 trial?
Would you consider reserving CDK4/6 Inhibitors as second line treatment in patients with advanced HR+ HER2 negative breast cancer given SONIA and PALMIRA trial results?